Optimization and in vitro/in vivo performance of paclitaxel-loaded nanostructured lipid carriers for breast cancer treatment

Pedro, Irma Danielle Rodrigues; Almeida, Osmar Patrício; Martins, Helen Rodrigues; Lemos, Janaína de Alcântara; Barros, André Luís Branco de; Leite, Elaine Amaral; Carneiro, Guilherme

doi:10.1016/j.jddst.2019.101370

Cited by 22 publications

(9 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…22,23 As a result, the application of NLC for the safe and effective delivery of drugs for cancer therapy has been successfully developed by many previous researchers. 24,25 Herein, we employed the mice drug-resistant esophagus carcinoma cells (AKR/Dox) as the model cell line. Moreover, NLC was selected as the carrier for the loading of Sfn and Dox (NLC/D-S) and was surface modified with folic acid (FA) as the targeting moiety to increase the tumor-homing of the DDS.…”

Section: ■ Introductionmentioning

confidence: 94%

“…In recent years, nanoparticle-derived DDSs have shown many advantages, including enhanced drug bioavailability, increased tumor-homing, and reduced cytotoxicity. − The DDSs adopted in cancer therapy were widely studied by previous reports with promising outcomes. − In particular, nanostructured lipid carrier (NLC) is a widely adopted organic platform for drug delivery, which composed of biocompatible lipids at solid or liquid state and was suitable for the delivery of hydrophobic drugs. , As a result, the application of NLC for the safe and effective delivery of drugs for cancer therapy has been successfully developed by many previous researchers. , …”

Section: Introductionmentioning

confidence: 99%

“… 22 , 23 As a result, the application of NLC for the safe and effective delivery of drugs for cancer therapy has been successfully developed by many previous researchers. 24 , 25 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Nanostructured Lipid Carriers Delivering Sorafenib to Enhance Immunotherapy Induced by Doxorubicin for Effective Esophagus Cancer Therapy

et al. 2020

View full text Add to dashboard Cite

The tumor microenvironment (TME) plays a significant role in weakening the effect of cancer immunotherapy, which calls for the remodeling of TME. Herein, we fabricated a nanostructured lipid carrier (NLC) to codeliver doxorubicin (Dox) and sorafenib (Sfn) as a drug delivery system (NLC/D-S). The Sfn was expected to regulate the TME of esophagus cancer. As a result, the immune response induced by Dox-related immunogenicity cell death could be fully realized. Our results demonstrated that Sfn was able to remodel the TME through downregulation of regulatory T cells (Treg), activation of effector T cells, and relieving of PD-1 expression, which achieved synergistic effect on the inhibition of primary tumor but also subsequent strong immune response on the regeneration of distant tumor.

show abstract

Section: ■ Introductionmentioning

confidence: 94%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Nanostructured Lipid Carriers Delivering Sorafenib to Enhance Immunotherapy Induced by Doxorubicin for Effective Esophagus Cancer Therapy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Many researchers showed the effect of loading PTX on nanocarriers in apoptosis induction. [48][49][50] Figure 7a-e demonstrates the cell apoptosis for the samples including control, UÀ PTX, PTX NCs, and PTXÀ CMCS NPs. It is obvious that the lowest cell death possesses to the control group with 0.687%, 2.103% of early and late apoptosis, respectively (Figure 7a).…”

Section: Cell Apoptosismentioning

confidence: 99%

Fabrication of Carboxymethyl Chitosan Nanoparticles to Deliver Paclitaxel for Melanoma Treatment

et al. 2020

View full text Add to dashboard Cite

In the present study, the effectiveness of paclitaxel nanocrystals (PTX NCs) encapsulated in carboxymethyl chitosan (CMCS) nanoparticles (CMCS−PTX NPs) as an anticancer drug is evaluated. The CMCS nanoparticles are produced via a cross‐junction microfluidic device where the PTX/CMCS concentration and flow rates in the device are optimized. The dynamic light scattering data show that the PTX NCs have a median diameter size of 230±90 nm, while the size of CMCS−PTX NPs is roughly 270±30 nm. The zeta‐potential result indicates less negative surface charge for the CMCS−PTX NPs as compared to the PTX NCs. Moreover, scanning electron microscopy micrographs, differential scanning calorimetry thermograms, and X‐ray diffraction patterns reveal that the physicochemical properties of the drug remain unaltered after perfusion through the microfluidic device. Cytotoxicity and cell endocytosis of PTX NCs and CMCS−PTX NPs are evaluated in vitro using G361 melanoma‐positive skin cells. The results reveal that the CMCS−PTX NPs increase the cellular uptake and cytotoxicity compared to the PTX NCs alone. In addition, the antitumor effect of CMCS−PTX NPs on B16 melanoma indicates the great potential of CMCS as a promising nano‐carrier for PTX NCs drug with potent inhibitory effect on the tumor growth.

show abstract

“…Lipid is one of the basic components of human body and can be obtained from a variety of sources. Most importantly, lipid carriers (LC) are usually non-toxic and suitable to load the hydrophobic drugs [25,26]. As many anticancer drugs, including CA, are reported to have low solubility in water, which severely limits their anticancer performance, the employment of LC as a carrier for the loading of anticancer drugs is considered a promising way and has been successfully practiced by many previous studies, in which the loaded drugs can be protected from the hostile tumour microenvironment and their availability is greatly increased as compared with free drugs [27,28].…”

Section: Introductionmentioning

confidence: 99%

Cinnamaldehyde and indocyanine green loaded lipid nanoparticles induced intracellular oxidative/thermal stress damage for effective cervical cancer therapy

Yan

2022

Micro & Nano Letters

View full text Add to dashboard Cite

The redox and thermal balances in cancer have been considered two fundamental bases for cancer progression. As a result, the development of novel action ways to disrupt these balances can therefore give potential anticancer benefits. Herein, cinnamaldehyde (CA) as a plant‐derived drug which could accelerate the H2O2 generation and elevate the reactive oxygen species (ROS) level in cancer cells, is employed to elevate the ROS level of cancer cells while the indocyanine green (ICG) as a photothermal agent was co‐delivered to induce oxidative/thermal stress damage to cells that provide a novel but effective way for effective cancer therapy. The CA and ICG were loaded in lipid nanoparticles to be a drug delivery system (DDS) for safe and effective drug delivery to tumour. The HeLa (human cervical cancer cell line) cells were employed as model and showed promising effects both in vitro and in vivo.

show abstract

Optimization and in vitro/in vivo performance of paclitaxel-loaded nanostructured lipid carriers for breast cancer treatment

Cited by 22 publications

References 43 publications

Nanostructured Lipid Carriers Delivering Sorafenib to Enhance Immunotherapy Induced by Doxorubicin for Effective Esophagus Cancer Therapy

Nanostructured Lipid Carriers Delivering Sorafenib to Enhance Immunotherapy Induced by Doxorubicin for Effective Esophagus Cancer Therapy

Fabrication of Carboxymethyl Chitosan Nanoparticles to Deliver Paclitaxel for Melanoma Treatment

Cinnamaldehyde and indocyanine green loaded lipid nanoparticles induced intracellular oxidative/thermal stress damage for effective cervical cancer therapy

Contact Info

Product

Resources

About